Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS greater than or equal to 1.5).

Trial Profile

Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS greater than or equal to 1.5).

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laromustine (Primary) ; Amsacrine; Cytarabine; Idarubicin
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes; Refractory anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HOVON-92-AML
  • Most Recent Events

    • 15 Mar 2012 This trial has been completed in Belgium and discontinued in Netherlands as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual initiation date (Sep 2008) added as reported by European Clinical Trials Database.
    • 15 Mar 2012 Planned End Date changed from 30 Sep 2012 to 12 Apr 2013 as reported by European Clinical Trials Database
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top